Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other ...
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our P/B Growth Investor model based on the published ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback